Agennix AG Reports Financial Results for Fiscal Year 2010

By The Associated Press Wednesday, March 16, 2024

Get daily Bioscience Technology industry top stories and headlines - Sign up now!

newsvine diigo google
slashdot
Share
Loading...

Agennix AG (FRANKFURT: AGX) (XETRA: AGX) today announced financial results for the fourth quarter and fiscal year ended December 31, 2010.

Fiscal year 2010 compared to fiscal year 2009In 2010, net revenues decreased to EUR 0.2 million from EUR 7.7 million in 2009. The significant difference in revenues is primarily due to the recognition in the fourth quarter of 2009 of EUR 7.4 million of previously deferred revenue from the agreement with Yakult Honsha Co. Ltd. for the development of satraplatin in Japan. Revenue for 2010 was attributable to an out-license agreement for certain intellectual property from the Company's discontinued discovery program unrelated to talactoferrin. Research and development (R&D) expenses increased to EUR 29.4 million for the year ended December 31, 2010, compared to EUR 6.7 million for the same period in 2009. The increase in R&D expenses was primarily due to increased clinical trial costs related to the Company's Phase III trials with talactoferrin in non-small cell lung cancer (NSCLC) as a result of the inclusion of Agennix Incorporated operations for the entire year ended December 31, 2010. Administrative expenses decreased to EUR 10.0 million for 2010 compared to EUR 13.1 million for 2009. Included in administrative expenses for the year ended December 31, 2009, were approximately EUR 8.6 million in one-time merger-related(1) costs (banking fees, legal services, audit and other related services) and a credit to compensation cost of EUR (1.5) million as a result of the forfeiture of convertible bonds and stock options. There were no such one-time charges for the year ended December 31, 2010.

Net loss in 2010 increased to EUR 27.0 million from EUR 11.9 million in the preceding year. Net loss before income tax benefit increased to EUR 36.5 million in 2010 from EUR 13.1 million in 2009. Basic and diluted loss per share was EUR 1.07 for 2010 compared to EUR 1.31 for 2009.

Cash positionAt December 31, 2023 the Company had cash, cash equivalents, other current financial assets and restricted cash of EUR 79.3 million (December 31, 2009: EUR 11.5 million). Net cash burn for 2010 was EUR 34.5 million with EUR 7.6 million in the first quarter, EUR 9.9 million for the second quarter, EUR 7.8 million for the third quarter and EUR 9.2 million for the fourth quarter. Net cash burn is derived by adding net cash used in operating activities and purchases of property, equipment and intangibles. The figures used to calculate net cash burn are contained in the Company's respective consolidated statements of cash flows.

Comparison to previous year: fourth quarter 2010 compared to fourth quarter 2009Revenues for the three months ended December 31, 2023 were EUR 0 compared to EUR 7.5 million for the same period in 2009. R&D expenses for the fourth quarter of 2010 increased to EUR 9.5 million compared to EUR 2.9 million for the fourth quarter of 2009. Administrative expenses decreased for the fourth quarter of 2010 to EUR 3.6 million compared to EUR 5.2 million for the same quarter in 2009. Net loss for the fourth quarter of 2010 was EUR 7.6 million compared to EUR 1.3 million for the fourth quarter of 2009. Net loss before income tax benefit was EUR 10.2 million for the fourth quarter of 2010 compared to EUR 2.5 million for the fourth quarter of 2009. Basic and diluted loss per share was EUR 0.19 for the fourth quarter of 2010 compared to EUR 0.15 for the same period in 2009.

Quarter over quarter results: fourth quarter 2010 compared to third quarter 2010Revenues for the fourth quarter of 2010 were EUR 0 compared to EUR 0.2 million for the previous quarter. R&D expenses increased to EUR 9.5 million for the fourth quarter of 2010 compared to EUR 8.3 million for third quarter of 2010. Administrative expenses for the fourth quarter of 2010 increased to EUR 3.6 million compared to EUR 2.0 million for the previous quarter. The Company had a net loss of EUR 7.6 million in the fourth quarter of 2010 compared to EUR 11.2 million for the previous quarter. Net loss before income tax benefit was EUR 10.2 million in the fourth quarter of 2010 compared to EUR 14.2 million for the third quarter of 2010. Basic and diluted loss per share was EUR 0.19 for the fourth quarter of 2010 compared to EUR 0.54 for the previous quarter.

Torsten Hombeck, Ph.D., Chief Financial Officer, said: "During 2010, we made steady progress in advancing our development plans with our lead program, oral talactoferrin. That progress is continuing with the recent completion of enrollment in the FORTIS-M Phase III trial in non-small cell lung cancer."

Dr. Hombeck continued, "In 2010 we also successfully refinanced the Company, including a major offering in which we raised approximately EUR 76 million in net proceeds. We believe we now have sufficient funding to achieve our key near- and mid-term development goals with talactoferrin, including, importantly, obtaining topline data from our first Phase III trial in non-small cell lung cancer as well as from the Phase II portion of our planned Phase II/III trial in severe sepsis."

Talactoferrin achievements and updateThe Company earlier today announced the completion of enrollment in the FORTIS-M Phase III registration trial. The FORTIS-M trial is a global randomized, double-blind trial evaluating talactoferrin plus best supportive care compared to placebo plus best supportive care in patients with NSCLC whose disease has progressed following two or more prior treatment regimens. The study enrolled 742 patients at over 160 sites globally. As also announced, Agennix currently expects topline data from the FORTIS-M trial in the first half of 2012.

The Company also provided an update on the planned Phase II/III trial evaluating talactoferrin in patients with severe sepsis. This trial will enroll approximately 350 patients at sites mainly in the U.S. and Europe and is currently expected to initiate in the second quarter of 2011.

Financial guidanceThe Company provided the following updated financial guidance:

Cash Position: Based on the current financial position of the Company, management believes that the Company will have sufficient cash to fund its operations well into the second half of 2012. This should enable the Company to obtain topline data in the FORTIS-M trial and to complete the Phase II portion of the planned Phase II/III trial with talactoferrin in severe sepsis, assuming no significant changes to currently projected timelines. This projected cash reach also assumes that the EUR 15 million loan made to the Company by dievini Hopp BioTech holding GmbH & Co. KG will not need to be re-paid prior to the release of topline results from both the FORTIS-M trial and the Phase II portion of the Phase II/III trial in severe sepsis.

Revenues: Management expects no substantial cash generating revenues for 2011. This guidance does not consider cash revenue from potential partnering of the Company's product candidates due to the uncertainty of the timing of such events.

R&D Expenses: For 2011, the Company expects R&D expenses to increase compared to 2010 due to an expected increase in talactoferrin clinical trial-related costs. The talactoferrin Phase III FORTIS-M trial in NSCLC has recently completed enrollment. In addition, the Company plans to initiate further clinical testing with talactoferrin in severe sepsis.

Administrative Expenses: Administrative expenses in 2011 are expected to increase moderately compared to 2010 as the Company plans to initiate certain critical pre-commercialization efforts.

2011 corporate calendarThe Company reported the dates for its 2011 corporate calendar as follows:

First quarter financial results: May 4 Annual Shareholders Meeting: May 10 Second quarter financial results: August 4 Third quarter financial results: November 3

Conference call scheduledAs previously announced, the Company has scheduled a conference call to which participants may listen via live webcast, accessible through the Agennix Web site at www.agennix.com (http://www.agennix.com) or via telephone. A replay will be available via the Web site following the live event. The call, which will be conducted in English, will be held today, March 16th at 15:00 CET/10:00 AM ET. The dial-in numbers for the call are as follows:

Participants from Europe: 0049 (0)69 71044 5598 0044 (0) 20 3003 2666 Participants from the U.S.: 1 646 843 4608

Please dial in 10 minutes before the beginning of the meeting.

About Agennix

Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company's most advanced program is talactoferrin, an oral therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer, as well as in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer, and Agennix plans to develop this program further for the treatment of severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase I testing, and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com (http://www.agennix.com) .

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG, including statements about the Company's future cash position. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond the control of the Company, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. There can be no guarantee that the results of the FORTIS-M trial or other ongoing studies with talactoferrin will be obtained when expected, will be positive or will be adequate to support a marketing approval. Additionally, there can be no guarantee that talactoferrin will be approved for marketing in any country or at all. There also can be no guarantee that the Company will have sufficient monies to fund operations well into the second half of 2012. Actual results could differ materially depending on a number of factors, and management cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Agennix is a trademark of the Agennix group.

(1) Agennix AG was formed by the business combination of Agennix, Incorporated and GPC Biotech AG and a EUR 15 million cash contribution by dievini Hopp BioTech holding GmbH & Co. KG. The business combination, which concluded with the merger of GPC Biotech into Agennix, became effective on November 5, 2009.

- Financials follow -

For the full management report and condensed consolidated financial statements and accompanying notes for the fiscal year ended December 31, 2010, please see the Investor Relations section of the Agennix website at http://www.agennix.com/index.php?optioncom_content&viewarticle&id122&Itemid77&langen (http://www.agennix.com/index.php?optioncom_content&viewarticle&id122&Itemid77&langen) .

Agennix AG Consolidated statement of operations Three months ended Twelve months ended December 31, December 31, 2010 2009 2010 2009 EUR 000 EUR 000 EUR 000 EUR 000 Revenue - 7,472 153 7,746 Research and development expenses (9,481) (2,857) (29,360) (6,719) Administrative expenses (3,625) (5,158) (9,982) (13,141) Amortization of intangible assets (1) (40) (52) (169) Impairment of intangible assets - (2,965) - (3,372) Other income, net 2,945 823 2,946 1,318 Finance income 194 257 202 1,446 Finance costs (229) (3) (400) (188) ---------- ---------- ---------- ---------- Net loss before tax (10,197) (2,471) (36,493) (13,079) Income tax benefit 2,577 1,141 9,491 1,141 ---------- ---------- ---------- ---------- Net loss for the period (7,620) (1,330) (27,002) (11,938) Basic and diluted loss per share, euro (EUR 0.19) (EUR 0.15) (EUR 1.07) (EUR 1.31) Average number of shares used in computing basic and diluted loss per share 40,926,000 9,137,687 25,246,336 9,137,687 See accompanying Notes to the consolidated financial statements Agennix AG Consolidated statement of financial position December 31, December 31, 2010 2009 EUR 000 EUR 000 Assets Non-current assets Property and equipment 3,462 3,416 Intangible assets 99,466 91,881 Other non-current assets 2,153 2,040 ------------- ------------- Total non-current assets 105,081 97,337 Current assets Trade receivables 4 35 Prepayments 316 596 Other current assets 1,443 259 Other current financial assets 30,197 - Cash and cash equivalents 49,016 11,413 ------------- ------------- Total current assets 80,976 12,303 Total Assets 186,057 109,640 Equity and Liabilities Equity attributable to the Company's equity holders Issued capital 41,884 18,705 Share premium 150,931 86,237 Other reserves 3,476 (1,863) Retained loss (43,499) (16,497) ------------- ------------- Total equity 152,792 86,582 Non-current liabilities Convertible bonds 210 210 Other non-current liabilities 18 33 Deferred tax liability 7,631 15,850 ------------- ------------- Total non-current liabilities 7,859 16,093 Current liabilities Trade payables 5,020 1,592 Accruals and other current liabilities 4,994 5,330 Short term note payable 15,392 - Deferred revenue, current portion - 43 ------------- ------------- Total current liabilities 25,406 6,965 ------------- ------------- Total liabilities 33,265 23,058 Total equity and liabilities 186,057 109,640 See accompanying Notes to the consolidated financial statements Agennix AG Selected financial data Consolidated cash flow statement Twelve months ended December 31, 2010 2009 EUR 000 EUR 000 Net cash used in operating activities (33,786) (21,355) Net cash used in investing activities (30,876) (12,722) Net cash provided by financing activities 101,969 13,248 Effect of exchange rate changes on cash and cash equivalents 294 458 ------------- ------------- Net increase (decrease) in cash and cash equivalents 37,603 (20,273) Cash and cash equivalents at beginning of period 11,413 31,686 ------------- ------------- Cash and cash equivalents at end of period 49,016 11,413 See accompanying Notes to the consolidated financial statements

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Bringing the Cell Image into Focus

Nov 2 2010

Improvements in transmission electron microscope (TEM) technology increase the power of this imaging tool for the study of cell biology.

Finding a Cure for Spinal Cord Injury with On-Demand LIMS

Oct 25 2010

The Miami Project to Cure Paralysis finds an on-demand laboratory information management system (LIMS) helps to accelerate discovery in its HCS projects.

Saving Cells: Image Processing for Improved Viability, Part II: Iterative Deconvolution

Oct 25 2010

3D light microscopy and deconvolution provide a means to investigate 3D structure, providing near-confocal quality images without the temporal requirements or potentially damaging phototoxicity associated with other 3D imaging technologies. This article is Part II in a series regarding viability, resolution improvement, and measurement in fluorescence imaging. Part I focused on spectral unmixing.

Saving Cells: Image Processing for Improved Viability

Sep 22 2010

This article is Part I of a two-part series regarding viability, resolution improvement, and measurement in fluorescence imaging. Part II will focus on deconvolution.

Evaluation of a New Nano-Type UV-Vis Spectrophotometer

Mar 3

Analysis of one- to four-microliter size samples for nucleic acids has become routine in many life science laboratories. However, until now, available instruments require considerable manipulation of the instrument and sample; some require manually recording the data. The user must typically lower and raise the arm manually, then wipe the sample manually from the target after each analysis. And fiberoptics used in some of these instruments are subject to deterioration.

Production of Recombinant Proteins and Monoclonal Antibodies in Hollow Fiber Bioreactors

Jan 25

While well-understood, robust and convenient, classical batch-style 2-D culture on non-porous supports or 3-D suspension culture in other devices are really not very biologically relevant models. Cell culture conditions can affect the quality of the antibody or protein produced.

Selecting Robots for Use in Drug Discovery and Testing

Dec 6 2010

Drug discovery and testing, with their need for speed, repeatability and verification, are ideally suited to benefit from robot automation. It is therefore not surprising that robots have been at the forefront of automation developments in both these areas.

HP Scalable Network Storage Systems for Life Sciences

Sep 13 2010

Life sciences research today is advancing exponentially, each step bringing us closer to the realization of truly personalized medicine–preventive care and treatments designed specifically for each individual. In the near future, PCPGM healthcare researchers expect to be able to use predictive genetic testing to create custom treatment plans for individuals and deliver dramatic improvements over today’s one-size-fits-all approach. But research capabilities are only part of the equation; current storage and operating capacities must also evolve to accommodate ever-expanding amounts of data before the goal of personalized medicine can be realized.

Using the Tecan Genesis Workstation to Automate a Cytometric Bead Array (CBA) Immunoassay

Mar 11 2010

The poster describe the process involved in automating a Cytometric Bead Array (CBA) immunoassay developed to measure relative concentrations of serum antibodies against Tetanus (TT), Sperm Whale Myoglobin (SWM) and Keyhole Limpet Hemocyanin (KLH) in KLH-immunized volunteers.

Ensuring Quality in Assays Performed with Automated Liquid Handlers

Feb 2 2010

The focus of this presentation is to highlight the need of ensuring quality in important assays performed with automated liquid handlers. Nearly all assays performed within a laboratory are volume-dependent. In turn, all concentrations of biological and chemical components in these assays, as well as the associated dilution protocols, are volume-dependent. Because analyte concentration is volume-dependent, an assay’s results might be falsely interpreted if liquid handler variability and inaccuracies are unknown or if the system(s) go unchecked for a long period.

Inkjet System for Protein Crystallography

Feb 1 2010

X-ray crystallography is used routinely by scientists to obtain the three dimensional structure of a biological molecule of interest.Such information can be used to determine how a pharmaceutical interacts with a protein target and what changes might improve functionality. However, the crystallization of macromolecules still remains a serious hindrance in structural determination despite impressive advances in screening methods and technologies.

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Nov 9 2009

Action selection is modulated by external stimuli either directly or via memory retrieval. In a constantly changing environment, animals have evolved attention-like processes to effectively filter the incoming sensory stream. These attention-like processes, in turn, are modulated by memory. The neurobiological nature of how attention, action selection and memory are inter-connected is unknown. We describe here new phenotypes of the memory mutant radish in the fruit fly Drosophila.

Prokariotic Cell Collection in Denmark

Nov 6 2009

I would like to know about a prokariotic cell collection in Denmark. Is there a cell bank in this country? I need a Lactobacillus strain for a fermentation assay and this information about the bank is very helpful for me.

Request for Entries

Oct 16 2009

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Viewing SureFocus Slides

Jun 11 2010

A demonstration of SureFocus Microscope Slides in the review of AFB Smears. SureFocus Slides are a patent-pending breakthrough in tuberculosis detection, as their fluorescent staining circle remains visible during review, Fluorescence Microscopy.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14 2009

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.

Top Stories and Headlines
EVERYDAY!

FREE Email Newsletter

Information: